- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00637104
European Multicenter, Randomized, Comparative Efficacy/Safety Study of the Mar-Tyn TiN-Coated Stent (MARTIN)
A European Multicenter, Randomized, Single Blind Study of the MAR-Tyn Cobalt Chromium TiN-Coated Balloon-Expandable Stent in the Treatment of Patients With de Novo Coronary Artery Lesions
Study Overview
Status
Intervention / Treatment
Detailed Description
Occlusive coronary artery disease is predominantly caused by coronary atherosclerosis, a pathologic vascular condition characterized by abnormal lipid and fibrous tissue accumulation in the vessel wall. This condition may be accompanied by degenerative changes and/or calcification leading to stenosis (narrowing) of the luminal channel. Percutaneous Transluminal Coronary Angioplasty (PTCA) is a well-accepted method of non-surgical myocardial revascularization for selected patients with symptomatic occlusive coronary artery disease.
Restenosis is the most important challenge limiting the long-term success of coronary angioplasty. Symptomatic restenosis usually occurs 6 months after an angioplasty procedure. The rates of restenosis reported in numerous clinical trials vary from 13% to 57%. This variability may be attributed in part to differences in the methods used to assess the occurrence of restenosis and in the criteria used to define restenosis. Regardless of the exact percentage, restenosis remains the Achilles heel of angioplasty. Numerous pharmaceutical approaches to limit restenosis have been tested, but none have been successful to date.
It was chosen to coat the stent with Titanium Nitrate (TiN), which is an inert, biocompatible material, that creates a thin physical barrier to diffusion of toxic metal atoms, TiN creates a very smooth surface that is impossible to obtain with a metal alloy. This coating was applied to the cobalt chromium platform, "Numen", made of the L605 Cobalt-20 Chromium-15 Tungsten-10 Nickel alloy. This alloy contains the lowest Nickel percentage of Cobalt Chromium alloys used for surgical implants. The strut thickness of the platform is reduced to the minimum of 65 microns for optimal hemodynamic performance and to permit an ultra low profile delivery system. The "Numen" design complies with the requirements of the "LMS -Less Mismatch Stent" theory applied where multiple 1 mm high zigzags form the stent pattern to align the segments at 45° with respect to blood flow when the stent is expanded to its nominal diameter. TiN coating is being used commercially for their hard-wearing and chemical inactive properties, particularly for surgical tools. TiN features chemical stability, great hardness, excellent wear properties, low electric impedance, biocompatibility, hemocompatibility and the possibility, through the application process, to exchange the orientation of the grains, the hardness, the wear characteristics and also the biocompatibility (a nanocrystalline structure produces a chemical surface more suitable for the endothelial cells). The produced coatings were very fine grained and dense with a porosity within the film structure of less than 10 nm in diameter. Furthermore, in an iliac artery stent model in normal rabbits, safety and efficacy in reduced restenosis of the TiN coated Numen™ stent was assessed.
The special TiN coating of the Mar-Tyn stents is very promising in reducing the lesions and the causes of intima neoplasia.
This study is a multicenter (up to 8 European centers), prospective, randomized single blind study. This study has a 2-arm design assessing the safety and effectiveness of the Tin-coated MAR-Tyn stent to an uncoated control cobalt-chromium balloon-expandable stent (Vision, Abbott Vascular), both mounted on a Rapid Exchange Stent Delivery System. A total of 160 patients will be entered in the study and will be randomized on a 1:1 basis. Patients who meet the eligibility criteria will be either randomized to Treatment A or Treatment B. The patient will not know which stent will be implanted while the physician will be unblinded . Patients will be followed at 30 days, 6, and 12 months post-procedure, with all patients undergoing repeat angiography at 6 months. All adverse events up to the 1 year follow-up period will be collected and analyzed.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
- Name: Luigi Marras, Dr. MEng. PhD.
- Phone Number: +39 3346738578
- Email: luigi.marras@ibsmed.it
Study Contact Backup
- Name: Nader Shehata, Dr. Eng.
- Phone Number: +39 040 3755 639
- Email: Nader.shehta@ibsmed.it
Study Locations
-
-
-
Freiburg Im Breisgau, Germany, 79106
- Recruiting
- Department of Internal Medicine III (Cardiology), University of Freiburg im Breisgau
-
Contact:
- Christoph Hehrlein, Prof. MD
- Email: hehrlein@Medizin.Ukl.Uni-Freiburg.De
-
Principal Investigator:
- Christoph Hehrlein, Prof. MD
-
-
-
-
-
Roma, Italy
- Recruiting
- Campus Biomedico, Cardiologia
-
Contact:
- Germano Di Sciascio, Dr. MD
- Phone Number: +39 06225411
- Email: g.disciascio@unicampus.it
-
Principal Investigator:
- Germano Di Sciascio, Dr. MD
-
-
BA
-
Bari, BA, Italy
- Recruiting
- Policlinico Universitario di Bari-Emodinamica Interventista
-
Contact:
- Bortone
- Email: abortone@cardiochir.uniba.it
-
Principal Investigator:
- Alessandro Bortone, Dr. MD
-
-
MI
-
Milano, MI, Italy
- Recruiting
- Ospedale San Raffaele- Emodinamica e Cardiologia
-
Contact:
- Antonio Colombo, Dr. MD
- Email: colombo.antonio@hsr.it
-
Principal Investigator:
- Antonio Colombo, Dr. MD
-
-
Ra
-
Ravenna, Ra, Italy
- Recruiting
- Ospedale di Ravenna, U.O. Cardiologia
-
Contact:
- Marco Balducelli, Dr. MD
- Phone Number: +39 0544 285 388
- Email: ra.hocardioemo@ausl.ra.it
-
Principal Investigator:
- Marco Balducelli, Dr. MD
-
-
-
-
-
Maastricht, Netherlands
- Recruiting
- CARIM, Department of Cardiology
-
Contact:
- J. Waltenberger, Prof. MD
- Email: j.waltenberger@cardio.azm.nl
-
Principal Investigator:
- J. Waltenberger, Prof. MD
-
-
-
-
-
Lugano, Switzerland
- Recruiting
- Cardiocentro Ticino, Cardiologia
-
Contact:
- Tiziano Moccetti
- Email: tiziano.moccetti@cardiocentro.org
-
Principal Investigator:
- Tiziano Moccetti, Prof. MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients must meet ALL of the following criteria:
- The patient must be > 18 years of age;
- Female of childbearing potential must have a negative pregnancy test within 7 days of enrollment and utilize reliable birth control for eight months after enrollment
- Diagnosis of angina pectoris as defined by Canadian Cardiovascular Society Classification (CCS I, II, III, IV) OR unstable angina pectoris (Braunwald Classification B&C, I-II) OR patients with documented silent ischemia;
- Single treatment of de novo lesion in a major coronary artery in patients with single or multi-vessel disease; patients with multiple lesions can be included only if the other lesions do not require treatment;
- Target vessel diameter at the lesion site is >2.50mm and <3.5mm in diameter (visual estimate);
- Target lesion is >10mm and <22mm in length (visual estimate);
- Target lesion stenosis is >50% and <100% (visual estimate);
- At least TIMI II coronary flow;
- Acceptable candidate for coronary artery bypass surgery (CABG);
- Patient is willing to comply with the specified follow-up evaluation;
- Patient must provide written informed consent prior to the procedure using a form that is approved by the local Ethics Committee.
- Patient can be pre-treated with aspirin and clopidogrel or, alternatively, aspirin alone plus a loading dose of 300 mg of clopidogrel before procedure completion in case of urgent PCI
Exclusion Criteria:
Patients will be excluded if ANY of the following conditions apply:
- Patient has experienced a Q-wave or non-Q-wave myocardial infarction with documented total CK >2 times normal within the preceding 24 hours and the CK and CK-MB enzymes remains above normal at the time of treatment;
- Has unstable angina classified as Braunwald III B or C and A I-II-III, or is having a peri infarction;
- Unprotected left main coronary disease with >50% stenosis;
- Significant (>50%) stenosis proximal or distal to the target lesion that might require revascularization or impede runoff;
- Have an ostial target lesion;
- Have a target lesion in a venous graft;
- Angiographic evidence of thrombus within target lesion;
- Calcified lesion which cannot be successfully predilated;
- Documented left ventricular ejection fraction <=25%;
- Totally occluded vessel (TIMI 0 level);
- Impaired renal function (creatinine > 3.0 mg/dl) at the time of treatment;
- Pretreatment with devices other than balloon angioplasty;
- Target lesion has excessive tortuousity or angulation (> 45°) which makes it unsuitable for stent delivery and deployment;
- Target lesion involves bifurcation including a diseased side branch >=2 mm in diameter (either stenosis of both main vessel and major branch or stenosis of just major branch) that would require side branch stenting;
- Prior stent within 5mm of target lesion;
- Direct Stenting
- Recipient of heart transplant;
- Patient with a life expectancy less than 12 months;
- Known allergies to the following: aspirin, clopidogrel bisulfate (Plavix) and ticlopidine (Ticlid), heparin, cobalt, chromium, or contrast agent (that cannot be managed medically)
- Recent (6 months) cerebrovascular accidents or intracranial hemorrhage
- Any significant medical condition which in the investigator's opinion may interfere with the patient's optimal participation in the study;
- Currently participating in an investigational drug or another device study;
- Intervention of another lesion has occurred within 6 months before the index procedure;
- In the investigator's opinion, the lesion is not suitable for stenting.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A - Mar-tyn
It includes the implant of the Mar-tyn TiN coated stent
|
Implant of the Mar-tyn TiN coated stent
Other Names:
|
Active Comparator: B - Vision
Includes all the patients treated with the Vision stent
|
Implant of the Vision stent
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
in-stent minimum lumen diameter (MLD)
Time Frame: 6 months
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Composite of Major Adverse Cardiac Events (MACE) defined as death, myocardial infarction (Q wave and non-Q wave), emergent bypass surgery, thrombosis, or repeat target lesion revascularization
Time Frame: 30 days, 6 months, 12 months
|
30 days, 6 months, 12 months
|
Angiographic binary restenosis (>50% diameter stenosis) 6 months post-procedure. In-lesion minimum lumen diameter (MLD) at 6 months post-procedure.
Time Frame: 6 months
|
6 months
|
Target lesion revascularization (TLR) at 6 months post-procedure. Target vessel revascularization (TVR) at 6 months post-procedure.
Time Frame: 6 months
|
6 months
|
• Device success defined as achievement of a final residual diameter stenosis of <30% (by QCA), using the assigned device only. If QCA is not available, the visual estimate of diameter stenosis is used.
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Marco Balducelli, MD,FESC,FACC, Ospedale "S.Maria delle Croci" - Ravenna, Italy
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IBS/03-2007
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
Seung-Jung ParkCardioVascular Research Foundation, KoreaRecruitingCoronary Stenosis | Coronary Artery Bypass Grafting | Coronary Artery Disease Progression | Percutaneous Coronary RevascularizationKorea, Republic of